International Foundation for Gastrointestinal Disorders
825 The Global Approach To Pediatric Functional Gastrointestinal Disorders
222 Report On The 7th International Symposium For FGIDs
News Article
Understanding how the federal government funds health programs is key to protecting and advancing research, education, and care for those affected by gastrointestinal (GI) disorders. At IFFGD, we are committed to helping patients, caregivers, and advocates stay informed about the federal budget and appropriations process—how funding decisions are made, where GI health research fits in, […]
Disorder
People with functional gastrointestinal (GI) disorders can have a variety of symptoms that range from painless diarrhea or constipation to pain associated with diarrhea and/or constipation (usually called irritable bowel syndrome). There is another, less common condition of abdominal pain that is chronic or frequently recurring; it is not associated with changes in bowel pattern […]
Testimony
IFFGD sent the following written comments to the FDA in connection with a November 9, 2000 meeting of the Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee to discuss Lotronex: Recent attention has focused on the new drug, Lotronex, for the treatment of Irritable Bowel Syndrome (IBS) symptoms in women who suffer from IBS-associated […]
News Article
International Foundation for Gastrointestinal Disorders (IFFGD) launches #IBSDilemma, a social campaign for Irritable Bowel Syndrome (IBS) Awareness Month this April. MOUNT PLEASANT, S.C., March 7, 2024 /PRNewswire/ — Irritable bowel syndrome (IBS) affects up to 5-10% of individuals worldwide, making it one of the most common gastrointestinal disorders. Although IBS does not shorten a person’s life span, living with IBS presents a myriad of […]